Management of Fenofibrate in Patients with Normalized Triglycerides

Indications and Discontinuation Criteria

For patients with triglycerides 200-499 mg/dL, fenofibrate may be considered after addressing lifestyle factors and when the benefits of ASCVD risk reduction outweigh potential risks, as recommended by the American College of Cardiology 1
The American College of Cardiology suggests that fenofibrate is indicated as adjunctive therapy to diet for treatment of severe hypertriglyceridemia to reduce the risk of pancreatitis, although this is not the primary indication in this context 1
If triglycerides are now within normal limits (<150 mg/dL), discontinuation of fenofibrate should be considered, according to guidelines from the American Heart Association, as published in Circulation 3
Discontinuation of fenofibrate is also recommended if there are no other compelling indications for continued therapy, as stated by the American Heart Association, as published in Circulation 3

After discontinuation of fenofibrate, a lipid panel should be checked 6-12 weeks later to ensure triglycerides remain within normal limits, as advised by the American College of Cardiology 1
The American College of Cardiology recommends monitoring liver function tests after discontinuation of fenofibrate, as they may have been affected by the therapy 1
Regular physical activity, weight management, reduced intake of saturated fats, limited dietary cholesterol, minimized trans fat intake, and reduced alcohol consumption are recommended to maintain normal triglyceride levels, according to the American Heart Association, as published in Circulation 3

The American College of Cardiology suggests that fenofibrate may be continued in patients with persistent mixed dyslipidemia despite statin therapy, due to its limited efficacy for reducing cardiovascular events compared to statins 2
If triglycerides remain ≥200 mg/dL despite lifestyle modifications, continuation of fenofibrate may be considered, as recommended by the American College of Cardiology and the American Heart Association, as published in Circulation 1, 3
For patients with diabetes and specific risk factors, combination therapy with fenofibrate may be beneficial, according to the American College of Cardiology 5

The American College of Cardiology warns that fenofibrate therapy carries a risk of myopathy, especially if combined with statins, and recommends regular monitoring of renal function 1
If the patient is on combination therapy with a statin, discontinuing fenofibrate may reduce the risk of myopathy, as suggested by the American College of Cardiology 1